{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:24:32Z","timestamp":1787790272528,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82404633"],"award-info":[{"award-number":["82404633"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05273-1","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:57:53Z","timestamp":1775786273000},"page":"12967-12982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of ustekinumab biosimilars for treating moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Yingying","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"19","key":"5273_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323(19):1945\u20131960. https:\/\/doi.org\/10.1001\/jama.2020.4006","journal-title":"JAMA"},{"issue":"3","key":"5273_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A et al (2020) Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol 156(3):258\u2013269. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4029","journal-title":"JAMA Dermatol"},{"issue":"5","key":"5273_CR3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/bjd\/ljae402","volume":"192","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Papp K, Trivedi M et al (2025) Efficacy and safety of the ustekinumab biosimilar abp 654 in patients with moderate-to-severe plaque psoriasis: a\u00a0randomized double-blinded active-controlled comparative clinical study over 52 weeks. Br J Dermatol 192(5):826\u2013836. https:\/\/doi.org\/10.1093\/bjd\/ljae402","journal-title":"Br J Dermatol"},{"issue":"7429","key":"5273_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/492S55a","volume":"492","author":"WH Boehncke","year":"2012","unstructured":"Boehncke WH (2012) Perspective: don\u2019t be superficial. Nature 492(7429):S55. https:\/\/doi.org\/10.1038\/492S55a","journal-title":"Nature"},{"issue":"7429","key":"5273_CR5","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1038\/492S62a","volume":"492","author":"S DeWeerdt","year":"2012","unstructured":"DeWeerdt S (2012) Psychodermatology: an emotional response. Nature 492(7429):S62-63. https:\/\/doi.org\/10.1038\/492S62a","journal-title":"Nature"},{"issue":"8","key":"5273_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14712598.2023.2235263","volume":"23","author":"SR Feldman","year":"2023","unstructured":"Feldman SR, Reznichenko N, Berti F et al (2023) Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between avt04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Expert Opin Biol Ther 23(8):759\u2013771. https:\/\/doi.org\/10.1080\/14712598.2023.2235263","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"5273_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2436607","volume":"35","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Narbutt J, Girolomoni G et al (2024a) Biosimilar sb17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52. J Dermatolog Treat 35(1):2436607. https:\/\/doi.org\/10.1080\/09546634.2024.2436607","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"5273_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2024.04.045","volume":"91","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Narbutt J, Girolomoni G et al (2024b) A randomized, double-blind, phase iii study assessing clinical similarity of sb17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis. J Am Acad Dermatol 91(3):440\u2013447. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.045","journal-title":"J Am Acad Dermatol"},{"key":"5273_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/ptt.S510156","volume":"15","author":"P Gisondi","year":"2025","unstructured":"Gisondi P, Bellinato F, Curic T, Girolomoni G (2025) Biosimilars for the treatment of moderate to severe chronic plaque psoriasis. Psoriasis (Auckl) 15:401\u2013410. https:\/\/doi.org\/10.2147\/ptt.S510156","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"5273_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa062382","volume":"356","author":"GG Krueger","year":"2007","unstructured":"Krueger GG, Langley RG, Leonardi C et al (2007) A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356(6):580\u2013592. https:\/\/doi.org\/10.1056\/NEJMoa062382","journal-title":"N Engl J Med"},{"issue":"9625","key":"5273_CR11","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/s0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (phoenix 1). Lancet 371(9625):1665\u20131674. https:\/\/doi.org\/10.1016\/s0140-6736(08)60725-4","journal-title":"Lancet"},{"issue":"4","key":"5273_CR12","first-page":"636","volume":"73","author":"KM Luba","year":"2006","unstructured":"Luba KM, Stulberg DL (2006) Chronic plaque psoriasis. Am Fam Physician 73(4):636\u2013644","journal-title":"Am Fam Physician"},{"issue":"4","key":"5273_CR13","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jaad.2024.10.104","volume":"92","author":"X Man","year":"2025","unstructured":"Man X, Zaharieva K, Pulka G et al (2025) A randomized phase iii study to compare efficacy and safety of bat2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 92(4):724\u2013731. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.104","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5273_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The prisma 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1):89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"issue":"1","key":"5273_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","volume":"38","author":"KA Papp","year":"2024","unstructured":"Papp KA, Lebwohl MG, Tha\u00e7i D et al (2024) Efficacy and safety of candidate biosimilar ct-p43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase iii study. BioDrugs 38(1):121\u2013131. https:\/\/doi.org\/10.1007\/s40259-023-00630-5","journal-title":"BioDrugs"},{"issue":"5","key":"5273_CR16","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s12325-025-03138-2","volume":"42","author":"K Papp","year":"2025","unstructured":"Papp K, Balser S, Nopora K, Rewerski P, Freudensprung B, Trieb M (2025) A randomised, double-blind trial to compare the efficacy, safety, and immunogenicity of the biosimilar ustekinumab fyb202 with reference ustekinumab in patients with moderate-to-severe plaque psoriasis. Adv Ther 42(5):2135\u20132149. https:\/\/doi.org\/10.1007\/s12325-025-03138-2","journal-title":"Adv Ther"},{"issue":"7","key":"5273_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.35541\/cjd.20220839","volume":"56","author":"Psoriasis Professional Committee DaVB, Chinese Medical Association","year":"2023","unstructured":"Psoriasis Professional Committee DaVB, Chinese Medical Association (2023) Chinese guidelines for the diagnosis and treatment of psoriasis (2023 edition). Chin J Dermatol 56(7):573\u2013625. https:\/\/doi.org\/10.35541\/cjd.20220839","journal-title":"Chin J Dermatol"},{"issue":"6","key":"5273_CR18","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20(6):1475\u20131503. https:\/\/doi.org\/10.3390\/ijms20061475","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5273_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G (2012) Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 3(2):80\u201397. https:\/\/doi.org\/10.1002\/jrsm.1037","journal-title":"Res Synth Methods"},{"key":"5273_CR20","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2017047","volume":"39","author":"S Shim","year":"2017","unstructured":"Shim S, Yoon BH, Shin IS, Bae JM (2017) Network meta-analysis: application and practice using stata. Epidemiol Health 39:e2017047. https:\/\/doi.org\/10.4178\/epih.e2017047","journal-title":"Epidemiol Health"},{"issue":"23","key":"5273_CR21","doi-asserted-by":"publisher","first-page":"12793","DOI":"10.3390\/ijms222312793","volume":"22","author":"R Singh","year":"2021","unstructured":"Singh R, Koppu S, Perche PO, Feldman SR (2021) The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci 22(23):12793\u201312816. https:\/\/doi.org\/10.3390\/ijms222312793","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5273_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/14712598.2025.2538608","volume":"25","author":"JC Szepietowski","year":"2025","unstructured":"Szepietowski JC, Reich A, Feldman SR et al (2025) Efficacy and safety of the ustekinumab biosimilar, bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28\u2011week results of the randomized, double-blind, phase 3 stellar-2 study. Expert Opin Biol Ther 25(8):913\u2013924. https:\/\/doi.org\/10.1080\/14712598.2025.2538608","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"5273_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/2047487318767199","volume":"25","author":"Z Wang","year":"2018","unstructured":"Wang Z, Carter RE (2018) Ranking of the most effective treatments for cardiovascular disease using sucra: is it as sweet as it appears? Eur J Prev Cardiol 25(8):842\u2013843. https:\/\/doi.org\/10.1177\/2047487318767199","journal-title":"Eur J Prev Cardiol"},{"key":"5273_CR24","unstructured":"World Health Organization: Global report on psoriasis. https:\/\/www.who.int\/publications\/i\/item\/9789241565189 (2016). Accessed May 12 2025"},{"issue":"1","key":"5273_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jaad.2025.03.018","volume":"93","author":"L Xia","year":"2025","unstructured":"Xia L, Miao G, Yang X et al (2025) Efficacy and safety of sysa1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: a multicenter, randomized, phase iii study. J Am Acad Dermatol 93(1):115\u2013123. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.018","journal-title":"J Am Acad Dermatol"}],"updated-by":[{"DOI":"10.1007\/s00210-026-05838-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000}}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05273-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05273-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05273-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:08:13Z","timestamp":1787789293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05273-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5273"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05273-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The authors identified minor errors regarding the figures that require correction to ensure the accuracy and clarity of the record.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00210-026-05838-0","URL":"https:\/\/doi.org\/10.1007\/s00210-026-05838-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"As this is meta analysis, ethical approval is not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}